Company research
EXAGEN INC.
CIK 1274737Updated Sep 26, 2026
SecurityXGN · NASDAQ · equity
Name history
EXAGEN DIAGNOSTICS INC · through May 18, 2017
XGN price & chart
Loading TradingView…
NASDAQ:XGN on TradingView ↗About the company
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The Company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE®-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, please visit Exagen.com or follow @ExagenInc on X.
In the news
No coverage from other publishers is available.
Recent filings
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 58,022,000Source | 44,689,000Source | 56,944,000Source | 86,221,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 8,197,000Source |
| GoodwillUSD | — | — | — | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 32,220,000Source | 22,036,000Source | 36,493,000Source | 62,391,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 10,855,000Source | 7,835,000Source | 6,551,000Source | 6,077,000Source |
| Assets, CurrentUSD | 48,893,000Source | 36,455,000Source | 47,841,000Source | 72,611,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,818,000Source | 6,584,000Source | 4,797,000Source | 4,143,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,435,000Source | 2,401,000Source | 3,286,000Source | 4,885,000Source |
| Other Assets, NoncurrentUSD | 756,000Source | 550,000Source | 616,000Source | 528,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 40,573,000Source | 35,149,000Source | 34,250,000Source | 43,761,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 23,000Source | 18,000Source | 17,000Source | 17,000Source |
| Additional Paid in CapitalUSD | 331,708,000Source | 303,853,000Source | 301,893,000Source | 297,970,000Source |
| Retained Earnings (Accumulated Deficit)USD | -314,282,000Source | -294,331,000Source | -279,216,000Source | -255,527,000Source |
| Stockholders' Equity Attributable to ParentUSD | 17,449,000Source | 9,540,000Source | 22,694,000Source | 42,460,000Source |
| Liabilities and EquityUSD | 58,022,000Source | 44,689,000Source | 56,944,000Source | 86,221,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 14,159,000Source | 13,506,000Source | 11,902,000Source | 9,623,000Source |
| Operating Lease, Liability, CurrentUSD | 1,226,000Source | 1,096,000Source | 976,000Source | 1,040,000Source |
| Accounts Payable, CurrentUSD | 4,153,000Source | 4,137,000Source | 3,131,000Source | 3,046,000Source |
| Operating Lease, Liability, NoncurrentUSD | 438,000Source | 1,664,000Source | 2,760,000Source | 4,493,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | 0Source |
| Other Liabilities, NoncurrentUSD | — | 157,000Source | 357,000Source | 867,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 6,327,000Source | 7,850,000Source | 7,531,000Source | 5,347,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | 0Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 643,000Source | 423,000Source | 264,000Source | 190,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 22,264,000Source | 19,822,000Source | 19,231,000Source | 28,778,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,100,000Source | 1,700,000Source | 2,200,000Source | 1,600,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,158,000Source | 1,763,000Source | 3,617,000Source | 4,704,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 3,020,000Source | 1,284,000Source | 474,000Source | -3,577,000Source |
| Increase (Decrease) in Accounts PayableUSD | 42,000Source | 308,000Source | 67,000Source | 901,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | -306,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,625,000Source | -13,279,000Source | -14,462,000Source | -32,144,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -626,000Source | -515,000Source | -804,000Source | -4,318,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 641,000Source | 515,000Source | 828,000Source | 4,318,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | 0Source | 239,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 24,435,000Source | -663,000Source | -10,632,000Source | -489,000Source |
| Repayments of Long-term DebtUSD | — | 0Source | 10,000,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 10,184,000Source | -14,457,000Source | -25,898,000Source | -36,951,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 32,420,000Source | 22,236,000Source | 36,693,000Source | 62,591,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,987,000Source | 1,719,000Source | 1,737,000Source | 1,732,000Source |
| Income Taxes Paid, NetUSD | 35,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,158,000Source | 1,763,000Source | 3,617,000Source | 4,704,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 378,000Source | 154,000Source | 156,000Source | 161,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | -111,000Source | -189,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | -295,000Source | — | — | — |
| GoodwillUSD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 5,506,000Source |
| Income Tax Expense (Benefit)USD | 51,000Source | 12,000Source | 33,000Source | -282,000Source |
| InterestExpenseNonoperatingUSD | 4,318,000Source | 2,234,000Source | — | — |
| Investment Income, InterestUSD | 289,000Source | 767,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -19,951,000Source | -15,115,000Source | -23,689,000Source | -47,387,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,540,000Source |
| Proceeds from Issuance of Common StockUSD | 3,398,000Source | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 22,000Source | 27,000Source | 61,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 66,575,000Source | 55,641,000Source | 52,548,000Source | 45,563,000Source |
| Cost of RevenueUSD | 27,776,000Source | 22,529,000Source | 23,092,000Source | 24,214,000Source |
| Selling, General and Administrative ExpenseUSD | 46,615,000Source | 41,373,000Source | 47,428,000Source | 52,018,000Source |
| Operating Income (Loss)USD | -14,070,000Source | -13,636,000Source | -22,837,000Source | -46,051,000Source |
| Income Tax Expense (Benefit)USD | 51,000Source | 12,000Source | 33,000Source | -282,000Source |
| Net Income (Loss) Attributable to ParentUSD | -19,951,000Source | -15,115,000Source | -23,689,000Source | -47,387,000Source |
| Earnings Per Share, BasicUSD per share | -0.93Source | -0.83Source | -1.34Source | -2.77Source |
| Earnings Per Share, DilutedUSD per share | -0.93Source | -0.83Source | -1.34Source | -2.77Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 21,558,245Source | 18,203,044Source | 17,679,467Source | 17,082,348Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 21,558,245Source | 18,203,044Source | 17,679,467Source | 17,082,348Source |
| Interest Expense (non-operating)USD | 4,318,000Source | 2,234,000Source | — | — |
| Additional Financial Items | ||||
| Cost, Depreciation and AmortizationUSD | 2,118,000Source | 1,724,000Source | 2,168,000Source | 1,557,000Source |
| Costs and ExpensesUSD | 52,869,000Source | 46,748,000Source | 75,385,000Source | 91,614,000Source |
| Current Income Tax Expense (Benefit)USD | 51,000Source | 12,000Source | 33,000Source | 24,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 5,506,000Source |
| Gross ProfitUSD | 38,799,000Source | 33,112,000Source | — | — |
| Income (Loss) Attributable to Parent, before TaxUSD | -19,900,000Source | -15,103,000Source | -23,656,000Source | -47,669,000Source |
| Interest ExpenseUSD | — | — | 2,335,000Source | 2,448,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 1,516,000Source | 830,000Source |
| Investment Income, InterestUSD | 289,000Source | 767,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | 1,540,000Source |
| Research and Development ExpenseUSD | 6,254,000Source | 5,375,000Source | 4,865,000Source | 9,876,000Source |
Filing attachments
d916977dex991.htm · 8-K · 2025-05-09
EX-99.1 2 d916977dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares CARLSBAD, Calif., May 9, 2025 (GLOBE NEWSWIRE) - Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursu…
Read attachment ↗d788679dex991.htm · 8-K · 2025-05-08
EX-99.1 4 d788679dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Exagen Inc. Announces Proposed Public Offering of Common Stock CARLSBAD, Calif., May 7, 2025 (GLOBE NEWSWIRE) - Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of co…
Read attachment ↗d788679dex992.htm · 8-K · 2025-05-08
EX-99.2 5 d788679dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Exagen Inc. Prices Public Offering of Common Stock CARLSBAD, Calif., May 8, 2025 (GLOBE NEWSWIRE) - Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $…
Read attachment ↗d811854dex41.htm · 8-K · 2025-04-28
EX-4.1 2 d811854dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDE…
Read attachment ↗d811854dex991.htm · 8-K · 2025-04-28
EX-99.1 5 d811854dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors $25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital April 28, 2025 Carlsbad, Calif., - Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan…
Read attachment ↗